Abstract
Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.
| Original language | English |
|---|---|
| Pages (from-to) | 3658-3668 |
| Number of pages | 11 |
| Journal | Clinical Cancer Research |
| Volume | 8 |
| Issue number | 12 |
| State | Published - Dec 1 2002 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. / Bahlis, Nizar J.; McCafferty-Grad, Jennifer; Jordan-McMurry, Ileana; Neil, Jim; Reis, Isildinha; Kharfan-Dabaja, Mohamed; Eckman, James; Goodman, Mark; Fernandez, Hugo F.; Boise, Lawrence H.; Lee, Kelvin P.
In: Clinical Cancer Research, Vol. 8, No. 12, 01.12.2002, p. 3658-3668.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma
AU - Bahlis, Nizar J.
AU - McCafferty-Grad, Jennifer
AU - Jordan-McMurry, Ileana
AU - Neil, Jim
AU - Reis, Isildinha
AU - Kharfan-Dabaja, Mohamed
AU - Eckman, James
AU - Goodman, Mark
AU - Fernandez, Hugo F.
AU - Boise, Lawrence H.
AU - Lee, Kelvin P.
PY - 2002/12/1
Y1 - 2002/12/1
N2 - Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.
AB - Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.
UR - http://www.scopus.com/inward/record.url?scp=0036896388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036896388&partnerID=8YFLogxK
M3 - Article
VL - 8
SP - 3658
EP - 3668
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 12
ER -